Patents Examined by James H. Alstrum-Acevedo
  • Mu opioid receptor agonist analogs of the endomorphins
    Patent number: 10919939
    Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic analogs of endomorphin. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: February 16, 2021
    Assignees: The Administrators of the Tulane Educational Fund, United States Department of Veterans Affairs
    Inventors: James E. Zadina, Laszlo Hackler
  • Pepducin design and use
    Patent number: 10913781
    Abstract: Disclosed here is the rational design and use of potent and specific GPCR antagonist pepducins based on GPCR regions such as the third intracellular loop and adjacent regions.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: February 9, 2021
    Assignee: Tufts Medical Center, Inc.
    Inventors: Athan Kuliopulos, Lidija Covic
  • Cyclic peptide binder against oncogenic K-Ras
    Patent number: 10913774
    Abstract: Cyclic peptides represented by (Formula 1) selectively bind the oncoprotein K-Ras G12D in vitro and in cellulo, where Z1 and Z2 are each L-propargylglycine (Pm), azidoornithine (OrnN3), or L-azidolysine (Az4), and V1-V2-V3-V4-V5 is an amino acid variable region having a sequence selected from the group consisting of SEQ ID NOs: 1-20.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: February 9, 2021
    Assignee: California Institute of Technology
    Inventors: Ryan K. Henning, Ashwin N. Ram, Samir Das, Arundhati Nag, James R. Heath
  • Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism
    Patent number: 10905736
    Abstract: In various embodiments, ezetimibe-associated apoA-I mimetic peptide are provided that show improved synergistic activity between ezetimibe and the apoA-I peptide in vivo. In certain embodiments the peptide component is a transgenic 6F and the ezetimibe-associated apoA-I mimetic peptide is an Ez-T6F peptide. Methods of making the Ez-apoA-I peptides are also provided. In certain embodiments the methods involve incubating ezetimibe and an apoAI mimetic peptide (e.g., T6F) in a solution comprising ethyl acetate and acetic acid or in a solution comprising ethyl lactate and lactic acid; and drying the solution to provide a dry ezetimibe-associated apoA-I mimetic peptide.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: February 2, 2021
    Assignee: The Regents of the University of California
    Inventors: Alan M. Fogelman, Srinivasa T. Reddy, Mohamad Navab
  • Compositions and methods of using islet neogenesis peptides and analogs thereof
    Patent number: 10899815
    Abstract: The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 26, 2021
    Assignee: Shenzhen HighTide Biopharmaceutical, Ltd.
    Inventors: Liping Liu, Ru Bai
  • Peptides and methods of using same
    Patent number: 10899797
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: January 26, 2021
    Assignee: SERPIN PHARMA, LLC
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Methods of preparing cytotoxic benzodiazepine derivatives
    Patent number: 10899775
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: January 26, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • Melanocortin ligands and methods of use thereof
    Patent number: 10899793
    Abstract: Certain embodiments of the invention provide a compound of formula (I): R1—C(?O)—W—X—Y—Z—N(R2)2??(I) or a salt thereof, wherein R1, R2, W, X, Y and Z are as defined herein, as well as methods of use thereof.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: January 26, 2021
    Assignees: Regents of the University of Minnesota, Torrey Pines Institute for Molecular Studies
    Inventors: Carrie Haskell-Luevano, Skye Ross Doering, Jon R. Appel, Marc A. Giulianotti, Richard A. Houghten, Clemencia Pinilla, Radleigh G. Santos
  • Stabilized glucagon solutions
    Patent number: 10888616
    Abstract: This invention relates to ready-to-use and safe solution compositions of glucagon suitable for administration by manual injection or by an insulin pump or other injection device to treat hypoglycemia. Said compositions comprise glucagon, an acid, anti-gelling polyol, a stabilizing-salt, viscosity reducer and an antioxidant, have a final pH between about 2 and 5, and is gel-free, chemically-stable, and pump-able.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: January 12, 2021
    Assignee: LATITUDE PHARMACEUTICALS, INC.
    Inventors: Hailiang Chen, Andrew Xian Chen, Norman Keith Orida
  • Solid phase peptide synthesis processes and associated systems
    Patent number: 10889613
    Abstract: Systems and processes for performing solid phase peptide synthesis are generally described. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. In certain embodiments, the inventive systems and methods can be used to perform solid phase peptide synthesis quickly while maintaining high yields. Certain embodiments relate to processes and systems that may be used to heat, transport, and/or mix reagents in ways that reduce the amount of time required to perform solid phase peptide synthesis.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: January 12, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Mark David Simon, Bradley L. Pentelute, Andrea Adamo, Patrick Louis Heider, Klavs F. Jensen
  • Channelrhodopsin variants and uses thereof
    Patent number: 10882892
    Abstract: CsChrimson light-activated ion channel polypeptides, their encoding polynucleotides, and variants thereof are provided. Methods of introducing and using CsChrimson light activated ion channels and variants thereof for to alter cell activity and function are also provided.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: January 5, 2021
    Assignees: Massachusetts Institute of Technology, The Governors of The University of Alberta
    Inventors: Nathan Klapoetke, Brian Yichiun Chow, Edward Boyden, Gane Ka-Shu Wong, Yongku Peter Cho
  • Peptidic TGF-beta antagonists
    Patent number: 10882894
    Abstract: The present invention provides peptidic TGF-? antagonists capable of inhibiting TGF-? signaling and disrupting the biochemical events that promote fibrosis and the epithelial-mesenchymal transition. The peptidic TGF-? antagonist may contain from 11 to 28 amino acid residues (for instance, may consist of from 12 to 16 amino acid residues) and may have the following structure (II): NH2? ETWIWLDTNMG-Xaa1-Y?COOH (II) wherein Xaa1 is any amino acid and Y is a peptide having from 0 to 9 amino acids. The peptidic TGF-? antagonists can advantageously be used for the prevention, treatment, and/or alleviation of the symptoms of a condition associated with an increase in TGF-? activity, including fibrosis (such as fibrosis of the skin, liver, lungs, and heart, among others) and cancer (including various carcinomas, such as squamous cell carcinoma, sarcomas, and metastatic cancers).
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: January 5, 2021
    Inventor: Anie Philip
  • Surfactant adhesive composition
    Patent number: 10870783
    Abstract: Provided herein is a surfactant adhesive protein comprising an amphiphilic peptide at the carbon or amine terminal of the protein, enabling homogeneous dispersion of several materials in various solvents and coating of the homogeneously dispersed particles on a hydrophilic or hydrophobic surface, particularly the homogeneous dispersion of hydrophilic or hydrophobic particles in a hydrophobic or hydrophilic solvent on the basis of strong adhesive strength of a mussel adhesive protein; the surface adhesive protein can be used as a surface coating agent requiring antibacterial or antiviral functions as well as a cosmetic product or an ink.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: December 22, 2020
    Assignee: KOLLODIS BIOSCIENCES, INC.
    Inventors: Sang Jae Lee, Bong Jin Hong
  • Composition for treating cellulite, and microneedle including same
    Patent number: 10869905
    Abstract: In a composition and a microneedle for a localized obesity treatment containing the same in accordance with the present disclosure, the composition in accordance with the present disclosure contains a gelatin, decomposes a fat in a body, and inhibits lipogenesis and fat deposition in the body.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: December 22, 2020
    Assignee: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Seung Yun Yang, Beum Soo An, Keum Yong Seong, Sung Min An
  • Molecular design of recombinant protein drug
    Patent number: 10869910
    Abstract: Provided is a mutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.
    Type: Grant
    Filed: February 14, 2016
    Date of Patent: December 22, 2020
    Assignees: Tsinghua University, BEIJING PROTGEN LTD.
    Inventors: Yongzhang Luo, Peng Liu, Xinan Lu
  • Methods and materials for monitoring myeloma using quantitative mass spectrometry
    Patent number: 10866248
    Abstract: The subject invention concerns methods and materials for diagnosing, monitoring the progress, and/or providing a prognosis for multiple myeloma and other conditions associated with antibody production in a person or animal. The methods of the invention utilize mass spectrometry for quantitative monitoring and detection of antibody produced by the plasma cells. The methods of the invention can be utilized for diagnosis, monitoring, and/or prognosis of multiple myeloma, monoclonal gammopathy, and other immunological or hematological conditions and disorders. In addition to detecting and quantifying antibody in a sample, other biological markers, such as serum albumin and/or beta-2-microglobulin, can also be detected and quantified using the present invention, and in combination with detection and quantification of antibody.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: December 15, 2020
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: John Matthew Koomen, Elizabeth Renee Remily, Kaaron Benson, Mohamad Hussein
  • Methods and compositions for improved cognition
    Patent number: 10864256
    Abstract: Provided herein are klotho polypeptide compositions and methods for improving cognitive function in an individual comprising treatment of with klotho polypeptides.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: December 15, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Dena Dubal
  • Solution phase method for preparing etelcalcetide
    Patent number: 10858389
    Abstract: The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: December 8, 2020
    Assignee: Amgen Inc.
    Inventors: Sheng Cui, Krishnakumar Ranganathan, Richard Crockett, Ying Chen, Aleksander Swietlow, Kevin Crossley, Yun Shi, Karel Decroos, Etienne Moniotte
  • Use of pertussis toxin as a therapeutic agent
    Patent number: 10849961
    Abstract: The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: December 1, 2020
    Assignee: Dignity Health
    Inventor: Jiong Shi
  • Compositions and methods for the treatment of carboxyhemoglobinemia
    Patent number: 10851153
    Abstract: Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: December 1, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Mark Thomas Gladwin, Jesus Tejero Bravo